Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00554918
Other study ID # CRUK-TRAPEZE-2100
Secondary ID CDR0000574585EUD
Status Completed
Phase Phase 2
First received November 6, 2007
Last updated August 6, 2013
Start date February 2005
Est. completion date June 2013

Study information

Verified date April 2008
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority Unspecified
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisolone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zoledronic acid may help relieve some of the symptoms caused by bone metastases. Radioactive substances, such as strontium chloride Sr 89, may help relieve bone pain caused by prostate cancer. Giving docetaxel together with prednisolone with or without zoledronic acid and/or strontium chloride Sr 89 may kill more tumor cells.

PURPOSE: This randomized phase II trial is studying the side effects and how well giving docetaxel together with prednisolone works with or without zoledronic acid and/or strontium chloride Sr 89 in treating patients with prostate cancer metastatic to bone that has not responded to hormone therapy.


Description:

OBJECTIVES:

Primary

- To assess the toxicity and tolerability of docetaxel with zoledronic acid.

- To assess the toxicity and tolerability of docetaxel with strontium chloride Sr 89.

- To assess the toxicity and tolerability of docetaxel with zoledronic acid and strontium chloride Sr 89.

Secondary

- Compare health economic endpoints between the treatment groups.

- Compare changes in bone mineral density between the treatment groups.

- Compare the biological profiling for prognostic and predictive indicators between the treatment groups.

Tertiary

- Compare median time to disease progression between the treatment groups.

- Compare pain progression-free survival (PFS) between the treatment groups.

- Compare PSA PFS between the treatment groups.

- Compare pain response between the treatment groups.

- Compare overall survival between the treatment groups.

- Compare quality of life between the treatment groups.

OUTLINE: This is a multicenter study. Patients are stratified according to treatment center and ECOG performance status (0 vs 1 vs 2). Patients are randomized to 1 of 4 treatment arms.

- Arm I: Patients receive docetaxel IV on day 1 and oral prednisolone once daily.

- Arm II: Patients receive docetaxel and prednisolone as in arm I and zoledronic acid IV over 15 minutes on day 1.

- Arm III: Patients receive docetaxel and prednisolone as in arm I and a single dose of strontium chloride Sr 89 IV on day 7 of course 2.

- Arm IV: Patients receive docetaxel and prednisolone as in arm I, zoledronic acid as in arm II, and strontium chloride Sr 89 as in arm III.

Treatment with docetaxel, prednisolone, and zoledronic acid repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Strontium chloride Sr 89 is given as a one time single dose.

Quality of life is assessed using the Euroqual (EQ-5D) and FACT-P at baseline and every 3 months during follow up.

After completion of study, patients are followed every 3 months.

Peer Reviewed and Funded or Endorsed by Cancer Research UK


Recruitment information / eligibility

Status Completed
Enrollment 300
Est. completion date June 2013
Est. primary completion date December 2008
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Diagnosis of 1 of the following:

- Histologically or cytologically proven prostate adenocarcinoma

- Multiple sclerotic bone metastases with PSA = 100 ng/mL without histological confirmation

- Radiological evidence of bone metastasis

- Prior hormonal therapy for prostate cancer including = 1 of the following:

- Bilateral orchidectomy

- Medical castration by luteinizing hormone-releasing hormone (LHRH) agonist therapy

- If receiving LHRH agonist therapy alone, this therapy should be continued

- Documented disease progression, defined by one of the following:

- Progressive disease after discontinuing hormone therapy

- Elevated and rising PSA, defined as 2 consecutive increases in PSA documented over a previous reference value

- PSA > 5ng/mL

- Progression of any unidimensionally or bidimensionally measurable malignant lesion

- At least 1 new lesion identified on bone scan

- No known brain or leptomeningeal metastases

PATIENT CHARACTERISTICS:

- ECOG performance status 0-2

- Life expectancy = 3 months

- Hemoglobin = 10g/dL

- ANC = 1,500/mm³

- Platelet count = 100,000/mm³

- Creatinine = 1.5 times upper limit of normal (ULN)

- ALT and AST = 1.5 times ULN (unless related to hepatic metastatic disease, where patients may be entered after discussion with one of the clinical advisors)

- Serum bilirubin = 1.5 times ULN

- Physically fit enough to receive trial treatment

- No malignant disease within the past 5 years, other than adequately treated basal cell carcinoma

- No symptomatic peripheral neuropathy = grade 2 (NCI CTC)

- No known hypersensitivity to bisphosphonates

- No condition, in the opinion of the investigator, that may interfere with the safety of the patient or evaluation of the study objectives

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- At least 4 weeks since prior flutamide, nilutamide, or cyproterone acetate with evidence of disease progression since cessation

- At least 6 weeks since prior bicalutamide with evidence of disease progression since cessation

- At least 4 weeks since prior estramustine and any adverse events must have resolved

- At least 2 months since prior treatment with a bisphosphonate for any reason

- No treatment with any other investigational compound within the past 30 days

- No prior cytotoxic chemotherapy for hormone refractory prostate cancer (HRPC), other than estramustine monotherapy

- No prior radionuclide therapy for HRPC

- No prior radiotherapy to more than 25% of the bone marrow or whole pelvic irradiation

- No concurrent enrollment in any other investigational clinical trial

Study Design

Allocation: Randomized, Primary Purpose: Treatment


Intervention

Drug:
docetaxel

prednisolone

zoledronic acid

Procedure:
quality-of-life assessment

Radiation:
strontium chloride Sr 89


Locations

Country Name City State
United Kingdom Aberdeen Royal Infirmary Aberdeen Scotland
United Kingdom Ayr Hospital Ayr Scotland
United Kingdom Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust Birmingham England
United Kingdom Velindre Cancer Center at Velindre Hospital Cardiff Wales
United Kingdom Gloucestershire Oncology Centre at Cheltenham General Hospital Cheltenham England
United Kingdom Edinburgh Cancer Centre at Western General Hospital Edinburgh Scotland
United Kingdom Beatson West of Scotland Cancer Centre Glasgow Scotland
United Kingdom Gloucestershire Royal Hospital Gloucester England
United Kingdom Ipswich Hospital Ipswich England
United Kingdom Crosshouse Hospital Kilmarnock Scotland
United Kingdom Mid Kent Oncology Centre at Maidstone Hospital Maidstone England
United Kingdom Christie Hospital Manchester England
United Kingdom Glan Clwyd Hospital Rhyl, Denbighshire Wales
United Kingdom Royal Marsden - Surrey Sutton England
United Kingdom Walsall Manor Hospital Walsall England
United Kingdom Wishaw General Hospital Wishaw Scotland

Sponsors (1)

Lead Sponsor Collaborator
University Hospital Birmingham

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety Yes
Primary Toxicity and tolerability of docetaxel and zoledronic acid Yes
Primary Toxicity and tolerability of docetaxel and strontium chloride Sr 89 Yes
Primary Toxicity and tolerability of docetaxel, zoledronic acid, and strontium chloride Sr 89 Yes
Secondary Health Care economic analysis No
Secondary Changes in bone mineral density No
Secondary Median time to disease progression No
Secondary Pain progression-free survival (PFS) No
Secondary PSA PFS No
Secondary Pain response No
Secondary Overall survival No
Secondary Quality of life No
See also
  Status Clinical Trial Phase
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A